Leading Breast AI Company, creator of industry-leading
Transpara®, promotes from within for new CEO
NIJMEGEN, Netherlands, April 25,
2024 /PRNewswire/ -- ScreenPoint Medical, today
announced a significant transition in its leadership as
Mark Koeniguer, the current CEO,
steps down from his position. Mark served as CEO since 2022 and
was instrumental in ScreenPoint's commercial growth and
success over the past 2 years.
The company's Board of Directors has appointed Pieter Kroese as the new Chief Executive Officer
effective April 25, 2024. Pieter
takes the role after serving as COO of ScreenPoint for over five
years. During that time, he has managed the transition of the
company from an early startup to a thriving enterprise with
hundreds of customers using ScreenPoint's flagship Transpara
software to support millions of scans a year.
"I am thrilled to lead ScreenPoint into its next phase of growth
and innovation," said Mr. Kroese. "I am deeply committed to
building upon the strong foundation we have and continuing to work
closely with our talented team to drive continued success. We are
already expanding screening capacity and capability through proven
reader support – we look forward to increasing our ability to
support providers and women moving forward."
Sir Michael Brady, Chairman of
the Board at ScreenPoint Medical and a co-founder of the company,
expressed enthusiasm about Pieter's appointment, stating, "Pieter's
remarkable leadership qualities, coupled with his depth of
knowledge of our product and industry, make him the perfect choice
to lead ScreenPoint into the future. His strategic mindset and
commitment to excellence align perfectly with our company mission
of early breast cancer detection. Pieter has been an integral part
of our growth to date and will provide seamless leadership through
this transition into our next chapter for our customers, partners,
and team."
Author of "No Longer Radical" and over a hundred peer-reviewed
publications on breast imaging, Dr. Rachel
Brem is a Transpara user and ScreenPoint Board Member. Dr.
Brem welcomed Mr. Kroese with the following: "Pieter has been an
integral part of the ScreenPoint team for years. I am confident
that his leadership will continue to deliver product excellence:
earlier detection with outstanding reading workflow and improved
patient outcomes. We continue to see these results from clinical
sites all over the world, including many here in the United States. No other Breast AI solution
has demonstrated the same results as Transpara, and I am confident
that the team will continue to push on these frontiers under
Pieter's leadership."
The entire team at ScreenPoint extends its gratitude to
Mark Koeniguer and wishes him every
success in the future, while warmly welcoming Pieter Kroese into his new role as CEO.
About ScreenPoint Medical
ScreenPoint Medical translates cutting edge machine
learning research into technology accessible by radiologists
to improve screening workflow, decision confidence
and breast cancer risk assessment. Transpara is trusted by
radiologists globally because it has been developed by experts in
machine learning and image analysis and updated with user feedback
from world-renowned breast imagers.
See all the proof
at: https://screenpoint-medical.com/evidence.
Photo:
https://mma.prnewswire.com/media/2397831/Pieter_Kroese_CEO_ScreenPoint_Medical.jpg
Logo:
https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/screenpoint-medical-leadership-transition-pieter-kroese-confirmed-as-ceo-302127714.html
SOURCE ScreenPoint Medical